|Bid||379.90 x 0|
|Ask||380.30 x 0|
|Day's Range||375.20 - 383.70|
|52 Week Range||280.80 - 477.70|
|PE Ratio (TTM)||23.25|
|Earnings Date||Nov 7, 2018|
|Forward Dividend & Yield||8.00 (1.80%)|
|1y Target Est||348.69|
By Julien Ponthus LONDON (Reuters) - European shares dipped on Wednesday as poor corporate earnings in the pharmaceutical sector weighed on sentiment already soured by trade tensions, with Washington preparing ...
Based on H Lundbeck A/S’s (CPH:LUN) earnings update in March 2018, the consensus outlook from analysts appear fairly confident, as a 17.82% increase in profits is expected in the upcomingRead More...
Revenue reached DKK 9,288 million in the first six months of 2018 representing an increase of 9% compared to the same period in 2017 Revenue of Abilify Maintena ® increased 16% to DKK 771 million Revenue ...
FDA approves Pfizer's (PFE) sNDA to expand the label of Xtandi to include the non-metastatic prostate cancer patient population.
Danish drugmaker Lundbeck (LUN.CO) said on Wednesday that it had reached a deal to pay $52.6 million to resolve a U.S. probe into its financial support of patient assistance charitable foundations. The company called the deal an agreement in principle and said the final terms of a settlement were subject to further negotiation with the U.S. Justice Department. Lundbeck said the agreement included no admission of wrongdoing by the company.
European markets were slightly higher Tuesday morning, as investors awaited critical news surrounding the Iran nuclear accord.
LUN.CO, LUN DC, HLUYY) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application for TRINTELLIX® (vortioxetine). TRINTELLIX is the first FDA-approved treatment for MDD where the U.S. labelling now includes data from the largest replicated clinical studies on an important aspect of cognitive function in acute major depressive disorder (MDD, depression).
H Lundbeck A/S (CPSE:LUN) outperformed the Pharmaceuticals industry on the basis of its ROE – producing a higher 21.54% relative to the peer average of 11.09% over the past 12Read More...
Pfizer's (PFE) pipeline candidate tafamidis, developed for the treatment of transthyretin cardiomyopathy (TTR-CM), meets the main goal in a late-stage study.
Though the large-cap pharma sector struggled a little after a strong start in 2018, it is largely expected to rebound as the year progresses.
Lundbeck today presented data at the American Epilepsy Society Annual Meeting in Washington, D.C. that demonstrates that the Refractory Epilepsy Screening Tool for LGS may help healthcare professionals identify patients who may benefit from further clinical evaluation for Lennox-Gastaut syndrome .
This highly levered, acquisition-focused growth story has come crashing down recently. It is eerily similar to when the highly-levered, acquisition-focused growth story of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) fell apart not too long ago. As we all know, VRX stock went bust and hasn’t recovered.
The Israel-based drugmaker on Monday tapped Kare Schultz as its new CEO. Schultz, who hails from Denmark-based Lundbeck, succeeds Dr. Yitzhak Peterburg, who has served as interim CEO since February.
The New CEO appointment at Teva (TEVA has once again shifted focus to the Generic Drug industry, which is presently facing several challenges.
Teva Pharmaceutical Industries Ltd named H Lundbeck A/S Chief Executive Kare Schultz as its new CEO and president on Monday, as it struggles with heavy debts and fierce competition for its generic drugs in the United States. Israel-based Teva's shares, which plunged after the company issued poor second-quarter results last month, rose 8 percent in early trade in Tel Aviv. Schultz will succeed Yitzhak Peterburg, who will continue as Teva's interim CEO until Schultz takes over.